top of page
The Professional Network for Healthcare Experts
Novartis licenses Alteogen Hybrozyme technology for multiple subcutaneous products
The agreement gives Novartis options to secure exclusive rights to develop and commercialise multiple subcutaneous products using Alteogen's ALT-B4 Hybrozyme technology.
nuaxia
Sep 42 min read
Alteogen signs $365 million Hybrozyme licensing deal for subcutaneous biologic
The agreement gives an undisclosed global pharmaceutical company worldwide rights to use Alteogen’s ALT-B4 technology to develop and commercialise a subcutaneous formulation of an existing biologic.
nuaxia
Aug 72 min read
bottom of page